This study investigated household transmission data for influenza (H1N1-2009) in Japan in order to quantify the agespecific risk of infection and estimate the impact of antiviral treatment on the risk of household transmission. Among a total of 1547 households, involving 4609 household contacts, the secondary attack ratio (SAR) was estimated to be 11.4%. School children aged 5 -18 years dominated the index cases. Age-specific infectiousness and susceptibility were highest among 0 -4-year olds, with SAR estimated at 19.4% and 29.6%, respectively. Zanamivir treatment within 24 and 24 -48 h of illness onset in index cases, respectively, reduced the risk of household transmission to 0.57 (95% CI 0.44, 0.73) and 0.58 (95% CI 0.38, 0.86) times that among those receiving the same treatment at > 48 h and those not receiving treatment. The preventive performance of antiviral treatment and prophylaxis should be further examined in randomized controlled trials.
Introduction
Influenza A (H1N1-2009) virus caused the first pandemic of the 21st Century. Confirmed cases were most frequent among children and adolescents, 1, 2 which is believed to reflect age-specificity of transmission and pre-existing immunity in the elderly. 3, 4 Although the virulence of this particular strain of the influenza virus appeared to be low, especially among adolescents and young adults, 5 a full understanding of the epidemiological risks of infection and an estimation of the treatment effects are crucial for elucidating the most effective countermeasure strategies to use in the future.
Epidemiological analysis of the specific risk of infection by H1N1-2009, together with statistical estimation of antiviral effects on secondary transmission, present two major H Nishiura, H Oshitani Household transmission of influenza H1N1-2009 in Japan technical challenges. The first is concerned with the difficulty of ascertaining all influenza cases. Although paediatric influenza cases were the most frequently reported, children may be more likely to be tested than adults, and such a biased diagnosis could arise from the frequent formation of school clusters. 6, 7 The second challenge is associated with 'dependent happening': because H1N1-2009 is transmitted from human to human, the risk of infection in a single individual is not independent of other individuals in the same population unit. 8 Accordingly, widely used epidemiological measurements of risk (e.g. odds ratio and risk ratio) are not strictly applicable to aggregate population data (e.g. population-based surveillance data). 9 Nevertheless, both these technical problems have been addressed by examining household transmission that conditions the risk of infection on exposure to a household index case and minimizes case ascertainment bias. 10, 11 Several household studies of H1N1-2009which identified the younger age groups as having a higher risk of infection than the older age groups, and estimated the preventive effects of antiviral treatment and prophylaxis on household transmissionhave been published. 10,12 -16 Although individuals in younger age groups were shown to be at a higher risk of infection in the early studies of H1N1-2009, 10,14 the sample sizes were small and the agegrouping tended to be crude (e.g. dichotomized into children and adults). Postexposure prophylaxis in households was highly effective in Japan during the early stages of the pandemic; 12 however, these early stages have various confounding factors, such as the containment effort and dramatic variations in contact behaviours within households (e.g. reduced contact with index cases on diagnosis). Antiviral treatment of index cases was demonstrated to be effective, but most published studies focused on oseltamivir treatment, for which the estimated risk reductions of household transmission were only marginally significant. 13 -15 Findings of the published household studies need to be validated in different population settings and with larger sample sizes.
To provide practical insights into the household transmission of H1N1-2009, the present study aimed to validate the agespecificity of infection and evaluate the effects of antiviral therapy on the risk of household transmission, with particular emphasis on zanamivir treatment among Japanese teenagers.
Patients and methods

CASE DEFINITION
In the present study, influenza cases of H1N1-2009 were defined as either medically diagnosed cases (inclusive of those diagnosed by rapid diagnostic testing and reverse transcription-polymerase chain reaction) or influenza-like illness cases (febrile patients [body temperature ≥ 37.5°C] with a cough and/or sore throat). Because of the retrospective nature of the household survey, medically diagnosed cases were only allegedly diagnosed at a medical facility. All cases were, therefore, dealt with as a single group of cases throughout the following analyses.
DATA COLLECTION
A retrospective household survey of 1614 non-randomly sampled households in Japan was conducted between May 2009 and February 2010. The household respondents were invited from a Japanese community of research monitors that is used for multiple study purposes. The community has been H Nishiura, H Oshitani Household transmission of influenza H1N1-2009 in Japan formed by respondent-driven sampling and maintained by a commercial research company located in Tokyo. The size of the community varies with time, but always involves more than 10 000 monitors from different households across Japan. The primary conditions for invitation to the survey were that: (i) the household size (total number of household members) was two or more; and (ii) one or more household member(s) experienced symptomatic H1N1-2009 infection between May 2009 and mid-February 2010. Enrolment was based on area sampling of households (one respondent per household) across Japan, according to the regional population sizes. That is, voluntary participation was invited until the number of participants in each region reached a predetermined maximum number proportional to the regional population size. Initially 1614 households with a total of 6536 household members were enrolled. All participants were contacted by the investigators at least twice; additional contact was made when participants had questions or when clarification was required from participants regarding the household transmission status. The respondent from each household received remuneration based on the organizing company's point system. The survey was conducted in realtime during the course of the pandemic, to minimize recall bias, and was completed by the end of February 2010.
In addition to the presence of at least one H1N1-2009 case in the household, eligible households in the present study had to meet the following inclusion criteria: (i) the earliest case was diagnosed between October 2009 and mid-February 2010, to avoid confounding effects of containment efforts during the earlier time period and the summer school holiday in 2009; (ii) all exposed individuals (i.e. household contacts) shared the household with the first (index) case for at least one of the 7 days following illness onset in the index case; (iii) the time interval from illness onset of the index case to that of subsequent cases was ≤ 7 days, 10, 16 however, no adjustment of co-primary cases was imposed (i.e. two or more cases infected in the community 17 ); and (iv) both the index case and the household contacts were unvaccinated (or vaccinated within 14 days of illness onset in the index case). The protective effect of vaccination among child participants has been assessed and reported elsewhere. 18 Information on the household size, and age and gender of each household member, was collected. When a participant met the definition of an H1N1-2009 case, they were asked for their earliest date of symptom onset. When an index case underwent antiviral treatment, the name of the antiviral agent and the time from illness onset to the date of first treatment was queried. Similarly, when a household contact undertook antiviral prophylaxis, the time from illness onset in the index case to the first date of prophylaxis was recorded. Following published studies, 13, 15 the time delay from illness onset in the index case to prophylaxis or treatment was categorized into one of three groups: (i) within 24 h of illness onset; (ii) 24 -48 h after illness onset; and (iii) > 48 h after illness onset and those without treatment. Prior to the pandemic, the Japanese government issued a warning that oseltamivir should not be given to teenagers because of reported irrational behaviour among the administered patients (see Discussion). 19 Although this instruction did not restrict the use of oseltamivir among teenagers at high risk of severe disease and although oseltamivir was available in the form of dry syrup for those aged < 10 years, a substantial fraction of school-aged subjects H Nishiura, H Oshitani Household transmission of influenza H1N1-2009 in Japan aged ≥ 10 years undertook treatment and prophylaxis with the alternative antiviral agent, zanamivir.
ETHICAL CONSIDERATIONS
It was explained that enrolment in this study was voluntary and participants were given the explicit right to withdraw at any time. For each household, adult participants were informed of how the information would be used and assured of confidentiality of the responses. Written informed consent was obtained from all adult respondents. No names (only ID numbers) were assigned to each response. Because the survey did not directly impose prevention or treatment and only collected existing information, recorded in such a manner that the subjects could not be identified, the study did not formally involve human subjects and did not, therefore, require approval by a human research ethics committee.
STATISTICAL ANALYSES
The demographic and epidemiological characteristics of the index cases and their household contacts were documented. The secondary attack ratio (SAR), defined as the proportion of infected individuals among household contacts, 20 was analysed in relation to covariates measured at the index case and household contact levels using the univariate Fisher's exact test or the χ 2 -test. The 95% confidence interval (CI) of the SAR was computed using the Wilson score method. Subjects were stratified into four discrete age groups: (i) preschool (≤ 4 years old); (ii) school-aged (5 -18 years); (iii) 19 -50 years; and (iv) aged ≥ 51 years. Household size was also categorized as (i) ≤ 3, (ii) 4, and (iii) ≥ 5 members. 15 To estimate the univariate and multivariate odds ratio (OR) of infection for each variable among household contacts, a logistic model with a generalized estimating equation was used to account for clustering in households. 21 The serial interval (i.e. the time from symptom onset in an index case to symptom onset in secondary cases 22, 23 ) was estimated from all index and secondary case pairs. The level of statistical significance was set at P = 0.05. All statistical data were analysed using JMP statistical software, version 9.0.0 (SAS Institute Inc., Cary, NC, USA).
Results
Of the 1614 households surveyed, 1547 (95.8%) met all of the above criteria to be eligible for inclusion in the analysis, giving a dataset of 1547 index cases and 4609 household contacts. Of the 1547 index cases, 387 (25.0%) were allegedly diagnosed at a medical facility. Of the 4609 household contacts, 524 developed influenza in the household, so the SAR for the entire dataset was estimated to be 11.4% (95% CI 10.5, 12.3). A total of 96 secondary cases (18.3% of all secondary cases) were diagnosed at a medical facility. A comparison of the demographic and epidemiological characteristics between index cases and household contacts is shown in Table 1 . Children aged 5 -18 years dominated the index cases, and the age of the household contacts was significantly older than the age of index cases (P < 0.01 for the difference of age distributions, χ 2 -test).
The SAR by age group of the index cases reflects the age-specific infectiousness of the index cases and shows a clear age-dependent gradation, with the highest estimate among those aged 0 -4 years (Fig. 1A) . The SAR in this age group was estimated at 19.4% (95% CI 15.4, 24.2) . Similarly, the SAR by age group of household contacts, reflecting agespecific susceptibility of the household contacts, was also highest among those aged 0 -4 years, with the SAR being 29.6% (95% CI 24.8, 34.9) (Fig. 1B) . In addition to the 
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univariate association between age and the risk of household transmission, the 0 -4 years age group remained the most significant risk factor for infection when multivariate analysis was carried out ( Table  2 ). Household size was not significantly associated with the risk of household secondary transmission (Table 2) . Gender was also not significantly associated with infection among all subjects (data not shown), but adult females aged 19 -50 years were significantly more likely to be infected The 95% confidence interval (CI) of the SAR was derived using the Wilson score method and the 95% CI of OR was computed employing a logistic model involving a generalized estimating equation. Where OR is not shown the variables were used as the baseline. a Univariate OR of antiviral prophylaxis and treatment are age-adjusted. b Prophylaxis and treatment with oseltamivir was mainly among adults (68.9% and 71.7% among total of cases with oseltamivir prophylaxis and treatment, respectively). c Zanamivir was almost exclusively used for teenagers (100% and 96.5% among the total of cases with zanamivir prophylaxis and treatment, respectively).
than adult males in the same age group in households (P < 0.01; OR of female to male adults, 2.01; 95% CI 1.49, 2.72).
The SAR was also compared by antiviral prophylaxis and treatment ( Table 2 ). The proportions of subjects aged < 20 years with oseltamivir or zanamivir prophylaxis, among the total household contacts with this prophylaxis (across all age groups), were 31.1% and 100%, respectively. Prophylaxis using oseltamivir or zanamivir did not yield a significant reduction in the risk of household transmission. Only a few per cent of the household contacts taking oseltamivir and zanamivir implemented prophylactic treatment within 24 h of illness onset. The proportions of those aged < 20 years treated with oseltamivir and zanamivir were 28.3% and 96.5%, respectively, among the total household contacts with these treatments (across all age groups). The risk of household transmission among households in which the index cases received oseltamivir treatment within 24 h of illness onset was 0.62 (95% CI 0.37, 1.02) times that among those with the same treatment at > 48 h and those without the treatment. Oseltamivir treatment at 24 -48 h after illness onset in the index case did not yield a significant reduction in the risk of household transmission. Zanamivir treatment within 24 and 24 -48 h of illness onset in index cases, respectively, significantly reduced the risk of household transmission to 0.57 (95% CI 0.44, 0.73) and 0.58 (95% CI 0.38, 0.86) times that among those receiving the same treatment at > 48 h and those without the treatment.
The mean ± SD serial interval was estimated as 3.1 ± 1.9 days and the sample serial interval ranged from 0 to 7 days after illness onset in the index case (Fig. 2) . The median (lower and upper quartiles) was 3.0 (2.0, 4.0) days. There was no positive correlation or association between the serial interval and the SAR (Pearson's correlation coefficient, -0.04; not statistically significant).
FIGURE 2:
Distribution showing the time from illness onset in the index case (day 0) to illness onset in secondary cases in the households (n = 524; the potential presence of coprimary cases [first and second cases in the households who were infected in the community 17 ] has not been adjusted for) 
Discussion
The present study investigated the household transmission data of influenza (H1N1-2009) in 1547 eligible households in Japan. Although the efficacy and effectiveness of antiviral treatment with respect to clinical outcomes have been relatively well assessed among severe cases, 24 -26 the present survey was conducted because the household study is well suited to assess treatment-induced risk reduction in secondary transmission, explicitly. In agreement with published studies, 10, 14 clear age specificities in infectiousness and susceptibility were seen, and both infectiousness and susceptibility were highest among preschool children. The overall SAR was estimated at 11.4% (95% CI 10.5, 12.3), consistent with earlier findings for H1N1-2009 in other countries. 15, 16 The finding that early zanamivir treatment among teenage index cases significantly reduced the risk of secondary transmission within households was novel. Zanamivir treatment within 48 h of illness onset in the index case led to a risk reduction of approximately 10 -60% relative to delayed, or an absence of, zanamivir treatment. Because no estimate of zanamivir-induced risk reduction in household transmission of H1N1-2009 is available, 11, 26 the present study gives an important insight into the treatment-driven prevention of household transmission arising from school-aged index cases. The mean serial interval of 3.1 days was consistent with other published estimates. 10 The present dataset is specific because teenage cases in Japan were almost exclusively administered zanamivir (for treatment), whereas oseltamivir was given to children and adults for either prophylaxis or treatment. Although oseltamivir is available for children aged < 10 years in the form of a dry syrup, and despite the fact that the use of half a capsule of oseltamivir was permitted by the government for school-age children in the midst of the pandemic, there were concerns that oseltamivir treatment in teenagers may cause psychological and neuropsychiatric side-effects that include self-harm in some adolescent patients. Thus, before the pandemic, the Japanese government issued a warning that oseltamivir should not be given to teenagers. 19 This policy offered a unique opportunity to assess the treatment effect of zanamivir only among teenage index cases. The sample size of zanamivir treatment was sufficiently large because of the domination of school-age children among the index cases, permitting the conclusion that zanamivir treatment among teenagers significantly reduced the risk of household transmission.
Although no significant risk reduction of household transmission by antiviral prophylaxis was observed in the present study, caution is required in the interpretation of these results. First, although other studies showed oseltamivir prophylaxis to be efficacious in preventing household transmission, 11, 26 it should be noted that, in the present study, oseltamivir prophylaxis was generally only given to adults. Secondly, although prophylaxis, including zanamivir use, was highly effective in Japan during the early phase of the pandemic, 12 this previous study included data from the early pandemic period that involved various disease-control efforts and a school holiday. Thus, such confounding factors might have led to an overestimation of the efficacy of zanamivir. Indeed, the unclear preventive effect of zanamivir prophylaxis is consistent with a systematic review in which the sample size was underpowered. 11 Thirdly, the present study was underpowered to determine significant reductions in the risk of household transmission during antiviral prophylaxis, therefore the findings on the • Received for publication 4 January 2011 • Accepted subject to revision 6 January 2011
• Revised accepted 28 February 2011 Copyright © 2011 Field House Publishing LLP effects of prophylaxis are limited. Oseltamivir treatment within 24 h was, however, shown to yield an odds ratio of 0.62, which was not statistically significant, but is broadly consistent with published studies. 13, 15 The simple adjustment of the age-effect in the statistical model may not have been enough to correct for confounding factors. This is also a problem when an age-specific treatment strategy is employed. Ideally, in future, study design and sample size estimations of relevant household surveys should account for age-specific strategies of antiviral treatment in addition to agedependent infectiousness and susceptibility. Two other limitations of the present study were that estimates were based on nonrandom samples and the case definition relied on symptoms of cases. The former cannot be addressed by retrospective study design, but strict inclusion criteria were enforced for the analysis. Future randomized trials that account for the above-mentioned issues, with an appropriate sample size, are called for.
In conclusion, the present study demonstrated the presence of clear agespecificity in infectiousness and susceptibility in the transmission of influenza (H1N1-2009), and showed that early zanamivir treatment among teenage index cases induced a significant reduction in the risk of household transmission.
